Older HIV-infected individuals present late and have a higher mortality: Brighton, UK cohort study

BMC Public Health

Martin Fisher¹  Helen A Weiss²  Yvonne Gilleece¹  Duncan Churchill¹  Collins C Iwuji³ 

[1] Lawson Unit, Department of HIV/Genitourinary Medicine, Brighton and Sussex University Hospitals NHS Trust, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, United Kingdom;MRC Tropical Epidemiology Unit, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK;Africa Centre for Health and Population Studies, University of KwaZulu-Natal, P.O. Box 198, Mtubatuba 3935, South Africa

关键词: CD4 cell count;    Mortality;    Older adults;    Late presentation;    HIV;   

Others  :  1162284
DOI  :  10.1186/1471-2458-13-397

 received in 2012-07-17, accepted in 2013-04-04,  发布年份 2013

【 摘 要 】

Background

Initiating therapy with a low CD4 cell count is associated with a substantially greater risk of disease progression and death than earlier initiation. We examined factors associated with late presentation of HIV using the new European consensus definition (CD4 cell count <350 cells/mm³) and mortality.

Methods

Patients newly diagnosed with HIV infection at a UK clinic were recruited from January 1996 to May 2010. Factors associated with late presentation were assessed using logistic regression. Factors associated with mortality rates were analysed using Poisson regression.

Results

Of the 1536 included in the analysis, 86% were male and 10% were aged 50 years and older. Half the cohort (49%) had a CD4 cell count below 350 cells/mm³ at presentation (“late presentation”). The frequency of late presentation was highest in those aged 50 years or older and remained unchanged over time (64.3% in 1996-1998 and 65.4% in 2008-2010). In contrast, among those aged less than 50 years, the proportion with late presentation decreased over time (57.1% in 1996-1998 and 38.5% in 2008-2010). Other factors associated with late presentation were African ethnicity and being a male heterosexual.

The mortality rate was 15.47/1000 person-years (pyrs) (95%-CI: 13.00-18.41). When compared with younger adults, older individuals had a higher mortality, after adjusting for confounders (rate ratio (RR) = 2.87; 95%-CI: 1.88-4.40).

Conclusions

Older adults were more likely to present late and had a higher mortality. Initiatives to expand HIV testing in clinical and community setting should not neglect individuals aged over 50.

【 授权许可】

   
2013 Iwuji et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Health Protection Agency: HIV in the United Kingdom. 2011. Report. 2011
• [2]May M: Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21(9):1185-1197.
• [3]Emery S: Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008, 197(8):1133-1144.
• [4]El-Sadr WM: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355(22):2283-2296.
• [5]Opravil M: Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count >350 × 10(6)/l. AIDS 2002, 16(10):1371-1381.
• [6]Phillips AN: Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007, 21(13):1717-1721.
• [7]Sullivan AK: Newly diagnosed HIV infections: review in UK and Ireland. BMJ 2005, 330(7503):1301-1302.
• [8]Adler A, Mounier-Jack S, Coker RJ: Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care 2009, 21(3):284-293.
• [9]Burns FM: Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK. AIDS 2008, 22(1):115-122.
• [10]Lanoy E: Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 2007, 12(1):89-96.
• [11]Sabin CA: Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004, 18(16):2145-2151.
• [12]Stohr W: CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. HIV Med 2007, 8(3):135-141.
• [13]Castilla J: Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 2002, 16(14):1945-1951.
• [14]Wolbers M: Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med 2008, 9(6):397-405.
• [15]Klein D: Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr 2003, 32(2):143-152.
• [16]Manavi K: Heterosexual men and women with HIV test positive at a later stage of infection than homo- or bisexual men. Int J STD AIDS 2004, 15(12):811-814.
• [17]Krentz HB, Auld MC, Gill MJ: The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med 2004, 5(2):93-98.
• [18]Smith RD: HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS 2010, 24(13):2109-2115.
• [19]Borghi V: Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr 2008, 49(3):282-286.
• [20]Johnson M, Sabin C, Girardi E: Definition and epidemiology of late presentation in Europe. Antivir Ther 2010, 15(Suppl 1):3-8.
• [21]Gazzard BG: British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008, 9(8):563-608.
• [22]Antinori A: Late presentation of HIV infection: a consensus definition. HIV Med 2011, 12(1):61-64.
• [23]Zoufaly A: Late presentation for HIV diagnosis and care in Germany. HIV Med 2012, 13(3):172-181.
• [24]Dickson NP: Late presentation of HIV infection among adults in New Zealand: 2005-2012. HIV Med 2012, 13(3):182-189.
• [25]National Research Ethics Service: Does my project require review by a Research Ethics Committee?. [cited 2012 09 October 2012]; Available from: http://www.nres.nhs.uk/applications/approval-requirements/ethical-review-requirements/ webcite
• [26]Helleberg M: Late presenters, repeated testing, and missed opportunities in a Danish nationwide HIV cohort. Scand J Infect Dis 2012, 44(4):282-288.
• [27]Begovac J: Late presentation to care for HIV infection in Croatia and the effect of interventions during the Croatian Global Fund Project. AIDS Behav 2008, 12(4 Suppl):S48-S53.
• [28]Delpierre C: Correlates of late HIV diagnosis: implications for testing policy. Int J STD AIDS 2007, 18(5):312-317.
• [29]Perry N: HIV testing in acute general medicine admissions must be universally offered to reduce undiagnosed HIIV. HIV Medicine 2010, 11(Supp.1):7-8.
• [30]Fisher M: Late diagnosis of HIV infection: major consequences and missed opportunities. Curr Opin Infect Dis 2008, 21(1):1-3.
• [31]Grabar S, Weiss L, Costagliola D: HIV infection in older patients in the HAART era. J Antimicrob Chemother 2006, 57(1):4-7.
• [32]Manfredi R: HIV infection and advanced age emerging epidemiological, clinical, and management issues. Ageing Res Rev 2004, 3(1):31-54.
• [33]Girardi E, Sabin CA, Monforte AD: Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007, 46(Suppl 1):S3-S8.
• [34]Health Protection Agency: HIV in the United Kingdom. 2012. Report. 2012
• [35]Sudarshi D: Missed opportunities for diagnosing primary HIV infection. Sex Transm Infect 2008, 84(1):14-16.
• [36]Sabin CA: Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006, 20(1):67-71.
• [37]Lucas SB, Curtis H, Johnson MA: National review of deaths among HIV-infected adults. Clin Med 2008, 8(3):250-252.
• [38]Sobrino-Vegas P: Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009, 7(2):224-230.
• [39]Smit C: Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands. PLoS One 2008, 3(4):e1949.
• [40]Delpierre C: Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people. Eur J Public Health 2008, 18(3):345-347.
• [41]Babiker AG: Age as a determinant of survival in HIV infection. J Clin Epidemiol 2001, 54:16-21.
• [42]Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe Lancet 2000, 355(9210):7-1131.
• [43]Centers for Disease Control and Prevention: Revised recommendations for HIV of adults, adolescents and pregnant women in health care settings. MMWR - Morbidity & Mortality Weekly Report 2006, 50(No. RR-14):1-16.
• [44]Palfreeman A: Testing for HIV: concise guidance. Clin Med 2009, 9(5):471-476.
• [45]Centers for Disease Control and Prevention: HIV testing among pregnant women - United States and Canada, 1998-2001. MMWR - Morbidity & Mortality Weekly Report 2002, 51:1013-1016.
• [46]Stanley B, Fraser J, Cox NH: Uptake of HIV screening in genitourinary medicine after change to "opt-out" consent. BMJ 2003, 326(7400):1174.
• [47]Marks G: Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005, 39(4):446-453.
• [48]Vernazza P: Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bull Med Suisses 2008, 89:165-169.
• [49]Castilla J: Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005, 40(1):96-101.